| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.079 | 0.08 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.08 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.08 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.14 | 0.08 |